It's still cold & article land is lacking. It's supposed to be warmer tomorrow & stay fairly warm for the week. Most articles were still dealing with funding cuts & rising transmission rates in some areas. There were some on Gilead's new 2-drug combo. It's a single dose pill with lenacapavir that's in the 3rd stage of research. If it gets approval, this would add to available regimens for people living with HIV. It would further the use of lenacapavir, which should lower the price. Soon, most people will have single dose or long acting options. That's a far cry from where these regimens started.
That's about it for now, take care.
Cya...
No comments:
Post a Comment